Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

While awaiting finalization of its merger with AbbVie, Shire signed a deal with privately held ArmaGen to license technology that could enable Elaprase to be delivered across the blood-brain barrier. That would enable the Hunter syndrome therapy to treat CNS manifestations of the disease as well as systemic symptoms.


Related Content

Emerging Markets Earnings Roundup: AbbVie (Part 5)
More Than Window Dressing: Ornskov Seen As Key Asset In AbbVie’s Buyout Of Shire
Shire’s Elaprase For Hunter Syndrome To Undergo Long-Term Outcomes Study
Shire’s Elaprase Approved For Hunter Syndrome


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts